Table 2.
Prevalence of diagnoses
| Categories |
Prevalence, n (%) N = 491 |
No. Not Patient Prompted |
USPSTF Recommendationsfor Screening |
|---|---|---|---|
|
ENDOCRINE | |||
| Adrenal adenoma |
2 (0.4) |
2 |
NR |
| Diabetes mellitus Type 2 |
3 (0.6) |
3 |
B* |
| Dyslipidemia |
40 (8.2) |
40 |
A** |
| Chronic fatigue |
1 (0.2) |
1 |
NR |
| Hyperparathyroidism |
6 (1.2) |
6 |
NR |
| Hyperthyroidism |
2 (0.4) |
2 |
I |
| Elevated lipoprotein (a) |
12 (2.4) |
12 |
NR |
| Metabolic syndrome |
6 (1.2) |
6 |
NR |
| Obesity |
95 (19.4) |
88 |
B |
| Class I |
72 |
67 |
|
| Class II |
13 |
12 |
|
| Class III |
10 |
9 |
|
| Osteoporosis |
9 (1.8) |
8 |
B |
| Thyroid nodule |
4 (0.8) |
2 |
I |
| Hashimoto’s thyroiditis |
1 (0.2) |
1 |
I |
| Thyrotoxicosis |
1 (0.2) |
1 |
I |
| Vertebral compression fracture |
2 (0.4) |
2 |
NR |
|
TOTAL |
184 (37.4) |
174 |
|
|
MALIGNANCY | |||
| Non-melanoma skin |
8 (1.6) |
8 |
I |
| Melanoma |
7 (1.4) |
4 |
I |
| Prostate cancer |
4 (0.8) |
4 |
D |
| Renal cell carcinoma |
1 (0.2) |
1 |
NR |
| Pancreatic cancer |
1 (0.2) |
0 |
D |
|
TOTAL |
21 (4.2) |
17 |
|
|
PRE-MALIGNANT | |||
| Colon polyp (large, multiple, tubulovillous+) |
5 (1.0) |
5 |
A |
| PSA elevation |
6 (1.2) |
6 |
D |
| Night sweats |
2 (0.4) |
0 |
NR |
|
TOTAL |
13 (2.6) |
11 |
|
|
CARDIOVASCULAR | |||
| Aortic aneurysm, thoracic |
1 (0.2) |
1 |
NR |
| Aortic aneurysm, abdominal |
1 (0.2) |
1 |
B |
| Aortic dilatation (any area) |
2 (0.4) |
2 |
NR |
| Moderate aortic stenosis |
1 (0.2) |
1 |
NR |
| Aortic valve regurgitation |
2 (0.4) |
2 |
NR |
| Bicuspid aortic valve |
1 (0.2) |
1 |
NR |
| CAD, stable |
3 (0.6) |
3 |
D |
| CAD, unstable |
1 (0.2) |
0 |
NR |
| Chest pain |
4 (0.8) |
3 |
NR |
| LVH |
2 (0.4) |
2 |
NR |
| Patent foramen ovale |
1 (0.2) |
1 |
NR |
| Abnormal stress test |
2 (0.4) |
2 |
D, I*** |
| Congestive heart failure |
1 (0.2) |
0 |
NR |
| Peripheral artery disease |
1 (0.2) |
0 |
D |
|
TOTAL |
23 (4.6) |
19 |
|
|
GASTROENTEROLOGY | |||
| Barrett’s esophagus |
1 (0.2) |
1 |
NR |
| Crohn’s disease |
1 (0.2) |
1 |
NR |
| Diverticulitis |
4 (0.8) |
3 |
NR |
| Diverticulosis |
1 (0.2) |
1 |
NR |
| Esophagitis |
6 (1.2) |
5 |
NR |
| Helicobacter pylori |
4 (0.8) |
3 |
NR |
| Hemochromatosis |
1 (0.2) |
1 |
D |
| Hepatitis C |
1 (0.2) |
1 |
D |
| Splenomegaly |
2 (0.4) |
2 |
NR |
| Steatohepatitis |
8 (1.6) |
8 |
NR |
| Mesenteric abscess |
1 (0.2) |
0 |
NR |
| Hematochezia |
2 (0.4) |
0 |
NR |
|
TOTAL |
32 (6.4) |
25 |
|
|
NEUROLOGY | |||
| Cerebral infarction |
1 (0.2) |
0 |
NR |
| Lumbar stenosis |
1 (0.2) |
1 |
NR |
| Neuropathy |
6 (1.2) |
2 |
NR |
| Paresthesia |
12 (2.4) |
4 |
NR |
| Pituitary adenoma |
1 (0.2) |
1 |
NR |
| Seizure |
1 (0.2) |
1 |
NR |
| Syringomyelia |
1 (0.2) |
1 |
NR |
| Spinal syrinx |
1 (0.2) |
1 |
NR |
| Gliomatosis cerebri |
1 (0.2) |
0 |
NR |
| Transient ischemic attack |
1 (0.2) |
0 |
NR |
|
TOTAL |
26 (5.2) |
11 |
|
|
PULMONARY | |||
| COPD |
3 (0.6) |
3 |
D |
| Obstructive sleep apnea |
24 (4.9) |
11 |
NR |
| Pleural effusion |
1 (0.2) |
1 |
I |
| Pleural thickening |
1 (0.2) |
1 |
I |
| Pneumonitis |
2 (0.4) |
2 |
NR |
| Upper airway resistance |
1 (0.2) |
1 |
NR |
| Asthma |
1 (0.2) |
0 |
NR |
| LTBI |
1 (0.2) |
1 |
NR |
|
TOTAL |
34 (6.9) |
20 |
|
|
NEPHROLOGY | |||
| IGA nephropathy |
1 (0.2) |
1 |
NR |
| Medullary sponge kidney |
1 (0.2) |
1 |
NR |
| Nephrolithiasis |
3 (0.6) |
2 |
NR |
| Polycystic kidney disease |
2 (0.4) |
2 |
NR |
| Prerenal azotemia |
1 (0.2) |
1 |
NR |
| Renal insufficiency |
3 (0.6) |
3 |
NR |
|
TOTAL |
11 (2.2) |
10 |
|
|
OPHTHALMOLOGY | |||
| Macular degeneration |
3 (0.6) |
3 |
NR |
| Glaucoma |
4 (0.8) |
4 |
I |
| Diabetic retinopathy |
1 (0.2) |
1 |
NR |
|
TOTAL |
8 (1.6) |
8 |
|
|
PSYCHIATRIC | |||
| Depression |
9 (1.8) |
1 |
B |
| Eating disorder |
1 (0.2) |
1 |
NR |
| Adjustment disorder |
2 (0.4) |
0 |
NR |
| Anxiety |
8 (1.6) |
1 |
NR |
|
TOTAL |
20 (4.0) |
3 |
|
|
HEALTH HABITS | |||
| Alcohol abuse |
5 (1.0) |
1 |
B |
| Nicotine dependency |
43 (8.8) |
2 |
A |
|
TOTAL |
48 (9.8) |
3 |
|
|
OTHER | |||
| Hearing loss (severe/asymmetric) |
5 (1.0) |
3 |
NR |
| Seronegative spondyloarthropathy |
1 (0.2) |
0 |
NR |
| Infertility |
1 (0.2) |
0 |
NR |
| Otitis media |
1 (0.2) |
0 |
NR |
|
TOTAL |
8 (1.6) |
3 |
|
| TOTAL | 428 (87.0) | 304 | |
Abbreviations: PSA, prostatic surface antigen; CAD, coronary artery disease; LVH, left ventricular hypertrophy; LTBI, Latent Tuberculosis Infection; COPD, chronic obstructive pulmonary disease; USPSTF, United States Preventive Services Task Force.
Recommendations for average risk patient are considered Grade A- Strongly recommended; Grade B- Recommended; Grade C- No recommendation; Grade d- Recommend against routine use; Grade I- Insufficient evidence to recommend for or against the intervention; NR- No recommendation available.
*Screen in individuals with hypertension, 2 out of 3 individuals met this criteria.
**Screen for men age ±35 and women age ±45.
***D for adults with low risk; I for adults with increased risk for coronary heart disease. ^ elevated PSA did not result in diagnosis of prostate cancer